ACN vs EDIT · P/E 24, rev $17.60B vs rev $32.3M
Accenture plc (ACN) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
Accenture plc (ACN) is a information technology services company listed on US.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported ACN revenue for 2025-08-31 was $17.60B. Net income was $1.41B. Revenue was down 0.7% from 2025-05-31 to 2025-08-31. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
ACN currently screens at market cap $186.16B and trailing P/E 23.8. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the ACN and EDIT stock pages for the full models.
Not investment advice.